The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .
Lutein supplementation reduces plasma lipid peroxidation and C-reactive protein in healthy nonsmokers.
OBJECTIVE The aim of this study was to determine whether lutein affected biomarkers related to cardiovascular diseases ( CVD ) in healthy nonsmokers . METHODS A r and omized , double-blind , placebo-controlled trial of lutein supplementation was conducted in healthy nonsmokers . 117 eligible subjects were r and omly assigned to receive 10 or 20 mg/d of lutein or placebo for 12 weeks . Levels of plasma carotenoid concentrations , total antioxidant capacity ( TAOC ) , the lipoprotein profile , and antioxidant enzymes activities were determined at baseline and at 6 , and 12 weeks after the initiation of treatment . Biomarkers of oxidative damage to protein and lipids , and C-reactive protein ( CRP ) concentrations were measured at baseline and after supplementation . RESULTS Plasma lutein and TAOC significantly increased in both active treatment groups during 12 weeks . A significant reduction was found in malondialdehyde in the 20 mg lutein group . CRP concentration decreased in a dose-dependent manner for lutein supplementation , and there was a significant between-group difference in CRP between the 20 mg lutein and the placebo group . Serum CRP was directly related to the change in plasma lutein and TAOC for both active treatment groups . CONCLUSION The results support the possibility that lutein supplementation reduce biomarkers of CVD risk via decreased lipid peroxidation and inflammatory response by increasing plasma lutein concentrations and antioxidant capacity
The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .